Diabetes is the fastest-growing global health issue, with diabetic retinopathy (DR) being a common long-term microvascular complication in both type 1 and type 2 diabetes. Despite recent advancements in treatment, which have reduced diabetes-related visual impairment, DR remains the leading cause of preventable blindness in working-age adults. This Reprint, featuring eight research articles and six reviews, presents the latest molecular research and advances in DR and diabetic macular edema (DME). Topics include genetic susceptibility and the molecular basis of DR, the interrelationship between DR, DME, and diabetic nephropathy, multimodal imaging, functional tests for early DR detection, and improvements in DR screening through artificial intelligence. This Reprint also explores new therapeutic options for DR, including sirolimus-pretreated mesenchymal stem cells, dazotuftide, aldose reductase inhibitors, and the impact of modern antidiabetic treatments on endothelial progenitor cells, which can aid in restoring vascular function. Additionally, the potential role of natural products in DR treatment is examined. This new knowledge promises to enhance diagnosis and may form the basis for future therapeutic approaches.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : Grand Eagle Retail, Bensenville, IL, Etats-Unis
Hardcover. Etat : new. Hardcover. Diabetes is the fastest-growing global health issue, with diabetic retinopathy (DR) being a common long-term microvascular complication in both type 1 and type 2 diabetes. Despite recent advancements in treatment, which have reduced diabetes-related visual impairment, DR remains the leading cause of preventable blindness in working-age adults.This Reprint, featuring eight research articles and six reviews, presents the latest molecular research and advances in DR and diabetic macular edema (DME). Topics include genetic susceptibility and the molecular basis of DR, the interrelationship between DR, DME, and diabetic nephropathy, multimodal imaging, functional tests for early DR detection, and improvements in DR screening through artificial intelligence.This Reprint also explores new therapeutic options for DR, including sirolimus-pretreated mesenchymal stem cells, dazotuftide, aldose reductase inhibitors, and the impact of modern antidiabetic treatments on endothelial progenitor cells, which can aid in restoring vascular function. Additionally, the potential role of natural products in DR treatment is examined. This new knowledge promises to enhance diagnosis and may form the basis for future therapeutic approaches. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. N° de réf. du vendeur 9783725874309
Quantité disponible : 1 disponible(s)
Vendeur : PBShop.store US, Wood Dale, IL, Etats-Unis
HRD. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. N° de réf. du vendeur L1-9783725874309
Quantité disponible : Plus de 20 disponibles
Vendeur : PBShop.store UK, Fairford, GLOS, Royaume-Uni
HRD. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. N° de réf. du vendeur L1-9783725874309
Quantité disponible : Plus de 20 disponibles
Vendeur : California Books, Miami, FL, Etats-Unis
Etat : New. N° de réf. du vendeur I-9783725874309
Quantité disponible : Plus de 20 disponibles
Vendeur : CitiRetail, Stevenage, Royaume-Uni
Hardcover. Etat : new. Hardcover. Diabetes is the fastest-growing global health issue, with diabetic retinopathy (DR) being a common long-term microvascular complication in both type 1 and type 2 diabetes. Despite recent advancements in treatment, which have reduced diabetes-related visual impairment, DR remains the leading cause of preventable blindness in working-age adults.This Reprint, featuring eight research articles and six reviews, presents the latest molecular research and advances in DR and diabetic macular edema (DME). Topics include genetic susceptibility and the molecular basis of DR, the interrelationship between DR, DME, and diabetic nephropathy, multimodal imaging, functional tests for early DR detection, and improvements in DR screening through artificial intelligence.This Reprint also explores new therapeutic options for DR, including sirolimus-pretreated mesenchymal stem cells, dazotuftide, aldose reductase inhibitors, and the impact of modern antidiabetic treatments on endothelial progenitor cells, which can aid in restoring vascular function. Additionally, the potential role of natural products in DR treatment is examined. This new knowledge promises to enhance diagnosis and may form the basis for future therapeutic approaches. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. N° de réf. du vendeur 9783725874309
Quantité disponible : 1 disponible(s)
Vendeur : AussieBookSeller, Truganina, VIC, Australie
Hardcover. Etat : new. Hardcover. Diabetes is the fastest-growing global health issue, with diabetic retinopathy (DR) being a common long-term microvascular complication in both type 1 and type 2 diabetes. Despite recent advancements in treatment, which have reduced diabetes-related visual impairment, DR remains the leading cause of preventable blindness in working-age adults.This Reprint, featuring eight research articles and six reviews, presents the latest molecular research and advances in DR and diabetic macular edema (DME). Topics include genetic susceptibility and the molecular basis of DR, the interrelationship between DR, DME, and diabetic nephropathy, multimodal imaging, functional tests for early DR detection, and improvements in DR screening through artificial intelligence.This Reprint also explores new therapeutic options for DR, including sirolimus-pretreated mesenchymal stem cells, dazotuftide, aldose reductase inhibitors, and the impact of modern antidiabetic treatments on endothelial progenitor cells, which can aid in restoring vascular function. Additionally, the potential role of natural products in DR treatment is examined. This new knowledge promises to enhance diagnosis and may form the basis for future therapeutic approaches. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. N° de réf. du vendeur 9783725874309
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Buch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Diabetes is the fastest-growing global health issue, with diabetic retinopathy (DR) being a common long-term microvascular complication in both type 1 and type 2 diabetes. Despite recent advancements in treatment, which have reduced diabetes-related visual impairment, DR remains the leading cause of preventable blindness in working-age adults.This Reprint, featuring eight research articles and six reviews, presents the latest molecular research and advances in DR and diabetic macular edema (DME). Topics include genetic susceptibility and the molecular basis of DR, the interrelationship between DR, DME, and diabetic nephropathy, multimodal imaging, functional tests for early DR detection, and improvements in DR screening through artificial intelligence.This Reprint also explores new therapeutic options for DR, including sirolimus-pretreated mesenchymal stem cells, dazotuftide, aldose reductase inhibitors, and the impact of modern antidiabetic treatments on endothelial progenitor cells, which can aid in restoring vascular function. Additionally, the potential role of natural products in DR treatment is examined. This new knowledge promises to enhance diagnosis and may form the basis for future therapeutic approaches. N° de réf. du vendeur 9783725874309
Quantité disponible : 2 disponible(s)
Vendeur : preigu, Osnabrück, Allemagne
Buch. Etat : Neu. Molecular Research and Recent Advances in Diabetic Retinopathy | Buch | Englisch | 2026 | MDPI AG | EAN 9783725874309 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand. N° de réf. du vendeur 135542595
Quantité disponible : 5 disponible(s)